# Lifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health

- Link: https://www.thailand-business-news.com/pr-news/lifespan-portfolio-company-rejuvenate-bio-closes-6-million-financing-and-rd-collaboration-with-merck-animal-health
- Published: 2026-06-11T21:20:00+07:00
- Author: PR Newswire

|   |

_Milestone financing and R&D collaboration advances gene therapy programs targeting
chronic and age-related diseases in companion animals. _

NORWALK, Conn., June 11, 2026 /PRNewswire/ — Lifespan Vision Ventures (LVV), an 
investment firm focused on therapeutics that improve human healthspan, congratulates
its portfolio company Rejuvenate Bio on the successful close of a $6 million financing
round and the announcement of a strategic research and development collaboration
with Merck Animal Health.

The financing round was led by VCapital, with participation from Merck Animal Health,
Connecticut Innovations, and Digitalis. Proceeds will support continued advancement
of Rejuvenate Bio’s gene therapy platform and pipeline, including treatments designed
to address chronic and age-associated diseases in companion animals.

Alongside the financing, Rejuvenate Bio and Merck Animal Health have entered into
a strategic R&D collaboration focused on advancing a novel gene therapy program 
in animal health, leveraging Rejuvenate Bio’s proprietary platform technologies 
and translational expertise.

Andrew Worden, Founding Partner at Lifespan Vision Ventures stated, "We are proud
to see Rejuvenate Bio reach this important milestone. The confidence shown by Merck
Animal Health – both as an investor and a collaborator – speaks to the strength 
of the team and the promise of their science. Lifespan Vision Ventures is delighted
to continue supporting their mission to address some of the most significant unmet
needs in companion animal and human health."

Rejuvenate Bio is developing gene therapies aimed at extending healthy lifespan 
and treating chronic diseases across both veterinary and human health applications.
The company’s approach focuses on modifying biological pathways associated with 
aging through targeted genetic interventions.

**About Lifespan Vision Ventures**

Lifespan Vision Ventures is a global venture capital firm investing in early-stage
biotechnology companies developing breakthrough technologies to prevent and treat
age-related diseases. The firm partners with visionary founders advancing science-
driven solutions that promote healthy aging and extend human healthspan.

Contact: [info@lifespanvision.com](https://www.thailand-business-news.com/pr-news/info@lifespanvision.com)

**About Rejuvenate Bio**

Rejuvenate Bio is a biotechnology company dedicated to developing novel gene therapies
for chronic age-related diseases. Rejuvenate Bio has built a gene therapy pipeline
with huge potential in chronic disease by utilizing clinically validated gene targets
and a delivery approach that ensures well tolerated, durable expression. Founded
on scientific research developed at the Wyss Institute at Harvard Medical School,
Rejuvenate Bio has developed groundbreaking therapies to treat chronic age-related
disease in both humans and animals. The company is headquartered in San Diego, CA.

For more information, visit [www.rejuvenatebio.com](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4709554-1&h=2591585358&u=https%3A%2F%2Fwww.rejuvenatebio.com%2F&a=www.rejuvenatebio.com).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Lifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health ](http://www.prnasia.com/story/archive/4981674_AE81674_0?rand=184833)